TRCT
PRME icon

Tower Research Capital (TRC)’s Prime Medicine PRME Stock Holding History

Tower Research Capital (TRC)’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.7K Sell
6,683
-15,131
-69% -$50.3K ﹤0.01% 3362
2026
Q1 		$75.9K Buy
21,814
+21,007
+2,603% +$80K ﹤0.01% 2395
2025
Q4 		$2.8K Sell
807
-3,085
-79% -$13.7K ﹤0.01% 4469
2025
Q3 		$21.6K Sell
3,892
-8,354
-68% -$33.9K ﹤0.01% 3251
2025
Q2 		$30.2K Buy
12,246
+2,337
+24% +$3.6K ﹤0.01% 3393
2025
Q1 		$19.7K Buy
9,909
+8,512
+609% +$21.7K ﹤0.01% 2985
2024
Q4 		$4.08K Sell
1,397
-6,652
-83% -$23.4K ﹤0.01% 4520
2024
Q3 		$31.1K Buy
8,049
+2,892
+56% +$13.4K ﹤0.01% 2978
2024
Q2 		$26.5K Sell
5,157
-1,906
-27% -$11.6K ﹤0.01% 3575
2024
Q1 		$49.4K Sell
7,063
-13,948
-66% -$106K ﹤0.01% 2285
2023
Q4 		$186K Buy
21,011
+17,483
+496% +$135K ﹤0.01% 2168
2023
Q3 		$33.7K Buy
3,528
+385
+12% +$5K ﹤0.01% 2920
2023
Q2 		$46K Sell
3,143
-82
-3% -$1.15K ﹤0.01% 2648
2023
Q1 		$40K Buy
3,225
+2,852
+765% +$46.5K ﹤0.01% 2716
2022
Q4 		$7K Buy
+373
New +$6.74K ﹤0.01% 4604

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Tower Research Capital (TRC)'s PRME Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Prime Medicine (PRME) stake by 69% in Q2 2026, selling an estimated $50.3K and leaving 6,683 shares worth $24.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3362.

Tower Research Capital (TRC) first reported a position in PRME in Q4 2022 and has held it in 15 quarters since. The position peaked at $186K in Q4 2023. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Tower Research Capital (TRC) held 6,683 shares of Prime Medicine worth $24.7K as of Q2 2026.
  • Tower Research Capital (TRC) sold 15,131 Prime Medicine shares in Q2 2026, an estimated $50.3K.
  • Prime Medicine made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3362 holding.
  • Tower Research Capital (TRC) first reported a position in Prime Medicine in Q4 2022 and has held it in 15 quarters since.
  • Tower Research Capital (TRC)'s Prime Medicine position peaked at $186K in Q4 2023.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.